Lipocine Inc Earnings
The next earnings date for Lipocine Inc is November 5, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of Lipocine Inc Earnings
| 11/05/2026 | $-0.39 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Lipocine Inc Earnings: Historical
| 08/04/2026 | Before Market | $-0.32 | 31.91% |
| 05/07/2026 | Before Market | $-0.54 | -12.50% |
| 03/10/2026 | --- | $-0.42 | 31.15% |
| 11/06/2025 | Before Market | $-0.59 | -9.26% |
| 08/14/2025 | Before Market | $-0.41 | -2.50% |
| 05/08/2025 | Before Market | $-0.35 | 0.00% |
| 03/05/2025 | Before Market | $0.33 | 182.50% |
| 11/07/2024 | Before Market | $-0.44 | 8.33% |
| 08/08/2024 | Before Market | $-0.56 | 28.21% |
| 05/09/2024 | Before Market | $0.66 | 197.06% |
More About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
“Lipocine Inc Earnings” Can Refer to the Lipocine Inc Earnings Date
Some people say “Lipocine Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Lipocine Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Lipocine Inc Stock on the Earnings Date
If you own Lipocine Inc stock (LPCN) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Lipocine Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Lipocine Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Lipocine Inc Earnings
You can contact us any time if you would like to ask questions about Lipocine Inc earnings or anything else related to the stock market.